DeepMed Research

Rifaximin

Generic Name: Rifaximin

Brand Names: Xifaxan, Zaxine

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₁N_₃O_₁₁

CAS Number: 80621-81-4

Unique Ingredient Identifier: L36O5T016N

Background: Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.

Indication: Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.

Associated Conditions: Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea

Clinical Trials

Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)

Not Applicable

Not yet recruiting

Conditions: Acute on Chronic Liver Failure

Interventions: Drug: Lactulose
Other: Standard Medical treatment
Drug: Rifaximin

First Posted Date: 2025-02-04

Last Posted Date: 2025-02-04

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 90

Registration Number: NCT06808009

Locations: 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Phase 1

Not yet recruiting

Conditions: Radiotherapy Induced Diarrhea
Acute Radiation Enteritis
Prostate Cancer
Cervical Adenocarcinoma
Bladder (Urothelial, Transitional Cell) Cancer
Rectal Adenocarcinoma
Pelvic Radiotherapy
Rifaximin

Interventions: Drug: Standard Care Chemoradiation
Drug: Rifaximin 550 MG

First Posted Date: 2025-01-20

Last Posted Date: 2025-01-20

Lead Sponsor: Mansoura University

Target Recruit Count: 80

Registration Number: NCT06783153

Locations: 🇪🇬
Mansoura University, Mansoura, Province, Egypt

Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.

Not Applicable

Recruiting

Conditions: SIBO

Interventions: Drug: Rifaximin (drug)

First Posted Date: 2025-01-13

Last Posted Date: 2025-05-16

Lead Sponsor: Xiuli Zuo

Target Recruit Count: 115

Registration Number: NCT06772064

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant

Not Applicable

Recruiting

Conditions: Chronic Liver Disease

Interventions: Drug: Rifaximin 550 MG
Other: SOC

First Posted Date: 2024-12-20

Last Posted Date: 2025-03-05

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 100

Registration Number: NCT06743464

Locations: 🇮🇳
Insitute of Liver and Biliary Sciences, New Delhi, Delhi, India

Efficacy of Rifaximin with NAC in IBS-D

Phase 2

Not yet recruiting

Conditions: IBS (Irritable Bowel Syndrome)
IBS-D (diarrhea-predominant)

Interventions: Drug: rifaximin 66mg + N-acetylcysteine 560mg three times daily
Drug: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Drug: Placebo

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-10

Lead Sponsor: Mark Pimentel, MD

Target Recruit Count: 225

Registration Number: NCT06727422

Rifaximin SSD in Dementia Trial

Phase 1

Recruiting

Conditions: Dementia Alzheimer Type
Dementia Associated With Cerebrovascular Disease

Interventions: Drug: Placebo
Drug: Rifaximin SSD 40 mg IR tablet

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-31

Lead Sponsor: Jasmohan Bajaj

Target Recruit Count: 20

Registration Number: NCT06718686

Locations: 🇺🇸
Richmond VA Medical Center, Richmond, Virginia, United States

Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

Not Applicable

Recruiting

Conditions: Bacterial Overgrowth Syndrome Small Bowel
Heart Failure with Preserved Ejection Fraction

Interventions: Drug: Rifaximin
Other: Standard HFpEF treatment

First Posted Date: 2024-10-22

Last Posted Date: 2024-10-22

Lead Sponsor: I.M. Sechenov First Moscow State Medical University

Target Recruit Count: 40

Registration Number: NCT06652087

Locations: 🇷🇺
Moscow, Moscow, Russian Federation

Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes

Phase 4

Terminated

Conditions: Liver Cirrhosis
Coagulation Disorder
Platelet Disorder
Endotoxemia

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-08

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 20

Registration Number: NCT06630572

Locations: 🇮🇹
Sapienza University of Rome - Policlinico Umberto I Roma, Rome, Italy

BCAA Vs. Rifaximin in Patients with Cirrhosis for Secondary Prophylaxis of HE

Not Applicable

Recruiting

Conditions: Hepatic Encephalopathy
Decompensated Cirrhosis
Minimal Hepatic Encephalopathy

Interventions: Drug: Oral Branched chain Amino acid
Drug: Rifaximin 550 MG
Drug: Lactulose
Drug: Placebo for Rifaximin 550mg
Drug: Placebo for BCAA

First Posted Date: 2024-08-05

Last Posted Date: 2025-02-14

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 336

Registration Number: NCT06538077

Locations: 🇮🇳
PGIMER, Chandigarh, India

Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension

Phase 1

Not yet recruiting

Conditions: Small Intestine Bacterial Overgrowth

Interventions: Drug: Rifaximin

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT06518850

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy